Loading
Every dated change on the records linked to Brain and spinal cord tumours (all types), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Regorafenib, the first arm, did not improve overall survival in newly diagnosed or recurrent glioblastoma; paxalisib and VAL-083 did not graduate; later arms continue.
Brigatinib produced radiographic responses in 10 percent of target tumours and 23 percent of all tumours, slowed growth of every tumour type and improved hearing in 35 percent of eligible ears in 40 heavily pretreated patients.
First targeted drug for grade 2 astrocytoma and oligodendroglioma after surgery (INDIGO trial).
Five-year event-free survival 68.
Three-year progression-free survival 87.
Depatuxizumab mafodotin added to radiotherapy and temozolomide did not improve overall survival in EGFR-amplified glioblastoma; stopped for futility.
Cognitive deterioration at 3 months 63.
Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.
Complete remission 49 percent with MATRix (methotrexate, cytarabine, thiotepa, rituximab) against 23 percent with methotrexate-cytarabine alone; two-year failure-free survival 76 percent after whole-brain radiotherapy and 75 percent after autologous transplant.
Quality-adjusted life-years 46.
IDH mutation, 1p/19q codeletion and H3 K27M began to define brain tumour types alongside microscopy; extended in 2021.